New York, USA - 21 Apr `17Celgene: Apremilast with NB-UVB

Official title: A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo. Phase II

In brief:

  • Procedure: Each participant will be compared with one side of the body to the other side. Enrolled subjects will be randomized to treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks, while the contralateral side of the body is covered by a special garment to prevent any UVB treatment.
  • Drug: Apremilast (oral tablet) 30 mg orally, twice daily. 

Recruitment status: completed

Start date: April 21, 2017    
Last Update: August 27, 2019

Contact: To learn more about this study, you or your doctor may contact the study research staff. Please refer to this study by its ClinicalTrials.gov identifier NCT03123016

FAQOther Questions

  • What are risks of oral and topical corticosteroids?

    Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...

  • What causes vitiligo?

    Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...

  • Vitiligo and hearing loss: any connection?

    In short, NO. Recent research shows no relationship between a degree of skin depigmentation and hearing loss severity in vitiligo patients. The results of this study showed tha...